Bevacizumab: a word of caution.
Kumar
Nishant
N
Sebastian
Rani
R
Harding
Simon
S
Pearce
Ian
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007267:Injections; D018811:Maternal Exposure / Q000009:adverse effects; D008875:Middle Aged; D011247:Pregnancy; D011379:Prognosis; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab